Free tool
FAERS Monitor: Azelex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020428 or its brand name (Azelex, Azelaic Acid). Reports on generic versions are filed under their own applications.
Reports
977
Serious
510
52% of reports
Hospitalization
192
Death reported
86
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective172
- pain142
- off label use125
- vomiting113
- abdominal pain upper111
- rash108
- product use in unapproved indication107
- gastrooesophageal reflux disease104
- migraine104
- paraesthesia103
- memory impairment100
- hypoaesthesia99
- blepharospasm95
- taste disorder93
- drug intolerance91
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 5 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 7 |
| 2009 | 9 |
| 2010 | 15 |
| 2011 | 6 |
| 2012 | 18 |
| 2013 | 10 |
| 2014 | 15 |
| 2015 | 27 |
| 2016 | 29 |
| 2017 | 19 |
| 2018 | 30 |
| 2019 | 39 |
| 2020 | 65 |
| 2021 | 80 |
| 2022 | 70 |
| 2023 | 88 |
| 2024 | 139 |
| 2025 | 146 |
| 2026 | 155 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,182 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| blepharospasmSignal | 95 | 329.7 | 271.9 | 30,344 |
| taste disorderSignal | 93 | 99.1 | 81.7 | 8,904 |
| gastrooesophageal reflux diseaseSignal | 104 | 27.8 | 23.2 | 2,672 |
| migraineSignal | 104 | 23.5 | 19.6 | 2,223 |
| drug intoleranceSignal | 91 | 20.3 | 16.7 | 1,656 |
| memory impairmentSignal | 100 | 15.7 | 13.0 | 1,368 |
| hypoaesthesiaSignal | 99 | 14.2 | 11.8 | 1,214 |
| paraesthesiaSignal | 103 | 14.1 | 11.7 | 1,249 |
| abdominal pain upperSignal | 111 | 11.6 | 9.7 | 1,076 |
| product use in unapproved indicationSignal | 107 | 9.3 | 7.8 | 793 |
| rashSignal | 108 | 5.3 | 4.5 | 384 |
| vomitingSignal | 113 | 5.2 | 4.4 | 385 |
| painSignal | 142 | 5.0 | 4.3 | 461 |
| off label useSignal | 125 | 3.1 | 2.6 | 180 |
| drug ineffectiveSignal | 172 | 2.8 | 2.5 | 212 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.